Francis Cuss, M.B., B.Chir., FRCP is a member of the Mural Oncology Board of Directors and serves as chair of the Compensation Committee.
Dr. Cuss is currently retired from full-time operational roles. Previously, he served as the executive vice president, chief scientific officer, and head of research and development at Bristol-Myers Squibb following his role as the senior vice president and head of research. Dr. Cuss served as an advisor to Biogen and to Seres Therapeutics, Inc., a publicly traded microbiome therapeutics company. Dr. Cuss has served on the board of directors of Novo Holdings A/S, a life sciences holding and investment company. He previously served on the board of directors of Rubius and of Glympse Bio.
Dr. Cuss received a B.A. and M.A. in natural sciences and an M.B., B.Chir. in medicine from Cambridge University.